Expression and clinical significance of p-mTOR, Beclin1 and Atg1 proteins in non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2020.05.011

Abstract

Abstract:

Objective

The expression levels of autophagy related proteins p-mTOR, Beclin1 and Atg1 in non-small cell lung cancer and normal lung tissues were detected to explore the mechanism of autophagy in the evolution of lung cancer.

Methods

Immunohistochemistry was used to determine the expression levels of p-mTOR, Beclin1 and Atg1 protein in 96 cases of non-small cell lung cancer, 64 cases of normal alveolar tissue and 60 cases of normal bronchial duodenal tissue, and to analyze the correlation between the expression differences and clinic pathological features.

Results

①Beclin1 and Atg1 proteins were significantly decreased in non-small cell lung cancer tissues and their expression levels were positively correlated. P-mTOR protein expression was significantly increased. ②Beclin1 protein expression decreased significantly with tumor enlargement, differentiation and lymph node metastasis. ③Atg1 protein expression decreased significantly with tumor enlargement and lymph node metastasis. ④The expression of p-mTOR protein increased significantly with the decrease of tumor differentiation and lymph node metastasis. ⑤p-mTOR was negatively correlated with Beclin1 and Atg1 expression.

Conclusion

Autophagy plays an important role in the pathogenesis of NSCLC. Beclin1 and Atg1, autophagy related proteins, play a synergistic role in tumor inhibition, and p-mTOR protein promotes the occurrence and development of NSCLC.

Key words: Non small-cell lung cancer, Alveolus, Bronchus, Beclin1, Atg1, p-mTOR

Xiuyi Zhang, Haoran Xu, Yadong Sun. Expression and clinical significance of p-mTOR, Beclin1 and Atg1 proteins in non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(05): 633-638.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.05.011

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I05/633

Figures/Tables 5

References 29

1	晁满香，毛　明，李建军. 细胞自噬在神经退行性病变中的作用[J]. 神经解剖学杂志，2018, 34(1): 137-140.
2	Gosavi P, Houghton FJ, McMillan PJ, et al. The Golgi ribbon in mammalian cells negatively regulates autophagy by modulating mTOR activity[J]. J Cell Sci, 2018, 131(3): 19-40.
3	Yang M, Yang XM, Yin DH, et al. Beclinl enhances cisplatin-induced apoptosis via Bcl-2-modulated autophagy in laryngeal carcinoma cells Hep-2[J]. Neoplasma, 2018, 65(1): 42-48.
4	Nobuo NN, Yuko F. Atg1 family kinases in autophagy initiation[J]. Cell Mol Life Sci, 2015, 72(16): 3083-3096.
5	杨剑敏，王海静，何　舟. PTEN、mTOR在HER2过表达乳腺导管内癌中的表达及意义[J]. 广东医学，2017, 38(14): 2165-2168.
6	Chi XS, Huang C, Li R, et al. Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy[J]. J Mol Neurosci, 2017, 61(4): 553-562.
7	Beth L, Yuan JY. Autophagy in cell death：an innocent convict？[J]. J Clin Invest, 2005, 115(10): 2679-2688.
8	Glick D, Barth S, Macleod KF. Autophagy: Cellular and molecular mechanism[J]. J Pathol, 2010, 221(1): 3-12.
9	Sun Y, Liu JH, Jin L, et al. Over-expression of the Beclin1 gene upregulates chemose nsitivity to anti-cancer drugs by enhancing therapy-induced apoptosis in cervix squamous carcinoma CaSki cells[J]. Cancer Lett, 2010, 294(2): 204-210.
10	Liang CY, Lee J, Kyung- SI, et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking[J]. Nat Cell Biol, 2008, 10(7): 776-787.
11	Li GD, Wu DQ, Li BY. Research progresses on the role of cell autophagy in cancer[J]. Clan J Cancer, 2009, 28(4): 445-448.
12	Futreal PA, Liu Q, Shattuck ED, et al. BRCA1 mutations in primary breast and ovarian carcinomas[J]. Science, 1994, 266(5182): 120-122.
13	Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation[J]. Science, 2000, 290(5497): 1717-1721.
14	Rebecca S, Deepa N, Ahmedin J. Cancer statistics，2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
15	Chen PL, Zhao T, Feng R, et al. Patterns and trends with cancer incidence and mortality rates reported by the China National Cancer Registry[J]. Asian Pac J Cancer Prey, 2014, 15(15): 6327-6332.
16	Akemi M, Tamotsu T, Yusuke K, et al. Expression of beclin1 in the mieroenvironment invasive ductal carcinoma breast：Correlation with prognosis and the cancer-stromal interaetion[J]. PLoS One, 2015, 10(5): e0125762.
17	Sarah VH, Beata W, Kevin JR, et al. The development of an immunohistochemical method to detect the autophagy-associated protein LC3-Ⅱ in human tumor xenografts[J]. Toxicol Pathol, 2011, 39(3): 516-523.
18	Efthimios S, Michael IK, Christos EZ, et al. LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas[J]. Am J Pathol, 2010, 176(5): 2477-2489.
19	晏　淼，朱正秋，卞保祥，等. Akt/mTOR信号通路在胃癌组织中的表达及其临床意义[J]. 中国全科医学，2011, 14(10C): 3442-3444.
20	张　刚，郭　剑，郝　鑫，等. PI3K/AKT/mTOR信号通路蛋白p-AKT及p-mTOR在胃癌组织中的表达及意义[J]. 临床与实验病理学杂志，2016, 32(10): 1149-1151，1155.
21	朱　伦，祁昔琴，吕胜祥. p-mTOR、GST-P和K-i 67在食管鳞状细胞癌中的表达及其相关性[J]. 肿瘤防治研究，2010, 37(4): 428-430.
22	许浩然，吕艳超，韩双双，等. 非小细胞肺癌组织中p-mTOR, p70s6k的表达变化及其临床意义[J]. 山东医药，2016, 56(11): 11-13.
23	王　亮，岳文涛，赵晓婷，等. 非小细胞肺癌组织mTOR/P70S6K表达临床意义的探讨[J]. 中华肿瘤防治杂志，2011, 18(1): 32-35.
24	杨金华，张慧青，穆　林. 非小细胞肺癌组织中p70S6K、ProGRP、CXCR2的表达情况及临床意义[J]. 癌症进展，2019, 17(11): 1310-1313.
25	Andrew T, Douglas HT, Daniel LG. Autophagy and cancer therapy[J]. Mol Pharmacol, 2014, 85(6): 830-838.
26	Beth L. Cell biology: autophagy and cancer[J]. Nature, 2007, 446(7137): 745-747.
27	Tanveer S, Emma M, Cathleen D, et al. Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells[J]. Cell Death Dis, 2018, 9(10): 990.
28	许浩然，何世杰，孙亚东，等. 非小细胞肺癌组织PTEN、p-Akt及p-mTOR的表达及意义[J]. 广东医学，2018, 39(5): 710-716.
29	张秀义，许浩然，景卫革，等. 非小细胞肺癌中p-mTOR、Beclin1及LC3蛋白的表达及意义[J]. 广东医学，2019, 40(7): 895-901.

临床及病理资料		例数	Beclinl蛋白表达		阳性率(%)	χ²值	P值
临床及病理资料		例数	阳性	阴性	阳性率(%)	χ²值	P值
性别
	男	62	20	42	32.26	0.0083	0.774
	女	34	10	24	29.41
年龄(岁)
	≤60	50	15	35	30.0	0.076	0.783
	>60	46	15	31	32.6
肿瘤大小(厘米)
	≤3	44	19	26	43.18	7.747	0.029
	>3	52	11	40	21.15
分化程度
	低中分化	58	9	49	15.52	16.881	0
	高分化	38	21	17	55.26
组织学类型
	鳞状细胞癌	50	16	34	32.0	0.027	0.869
	腺癌	46	14	32	30.43
淋巴结转移
	无	56	25	31	44.64	11.221	0.001
	有	40	5	35	12.5

临床及病理资料		例数	Beclinl蛋白表达		阳性率(%)	χ²值	P值
临床及病理资料		例数	阳性	阴性	阳性率(%)	χ²值	P值
性别
	男	62	20	42	32.26	0.0083	0.774
	女	34	10	24	29.41
年龄(岁)
	≤60	50	15	35	30.0	0.076	0.783
	>60	46	15	31	32.6
肿瘤大小(厘米)
	≤3	44	19	26	43.18	7.747	0.029
	>3	52	11	40	21.15
分化程度
	低中分化	58	9	49	15.52	16.881	0
	高分化	38	21	17	55.26
组织学类型
	鳞状细胞癌	50	16	34	32.0	0.027	0.869
	腺癌	46	14	32	30.43
淋巴结转移
	无	56	25	31	44.64	11.221	0.001
	有	40	5	35	12.5

临床及病理资料		例数	p-mTOR蛋白表达		阳性率(%)	χ²值	P值
临床及病理资料		例数	阳性	阴性	阳性率(%)	χ²值	P值
肿瘤分化程度
	低中分化	58	46	12	79.31	13.894	0
	高分化	38	16	22	42.11
组织学类型
	鳞状细胞癌	58	42	16	72.41	2.876	0.09
	腺癌	38	22	16	57.89
淋巴结转移
	无	56	30	26	53.57	10.371	0.001
	有	40	34	6	85.0

临床及病理资料		例数	p-mTOR蛋白表达		阳性率(%)	χ²值	P值
临床及病理资料		例数	阳性	阴性	阳性率(%)	χ²值	P值
肿瘤分化程度
	低中分化	58	46	12	79.31	13.894	0
	高分化	38	16	22	42.11
组织学类型
	鳞状细胞癌	58	42	16	72.41	2.876	0.09
	腺癌	38	22	16	57.89
淋巴结转移
	无	56	30	26	53.57	10.371	0.001
	有	40	34	6	85.0

临床及病理资料		例数	Atg1蛋白表达		阳性率(%)	χ²值	P值
临床及病理资料		例数	阳性	阴性	阳性率(%)	χ²值	P值
肿瘤大小(厘米)
	≤3	44	17	27	38.63	6.69	0.01
	>3	52	8	44	15.38
分化程度
	低中分化	58	15	43	25.86	0.002	0.96
	高分化	38	10	28	26.31
组织学类型
	鳞状细胞癌	50	13	37	26.0	0	0.992
	腺癌	46	12	34	26.09
淋巴结转移
	无	56	21	35	37.5	9.162	0.002
	有	40	4	36	10.0

Please choose a citation manager

Content to export